Login to Your Account



Mixed Signals from FDA

Waiting to Exhale: COPD Push 'Daxas' Patience of Developers

By Randy Osborne


Monday, April 19, 2010
"The most bizarre we've ever seen." That's how Jefferies & Co. analyst Corey Davis described the FDA advisory panel meeting earlier this month on Daxas (roflumilast), the drug candidate for chronic obstructive pulmonary disease from Forest Laboratories Inc. and Nycomed GmbH.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription